Document is current
Any future updates will be listed below
-
Authors
Storrar, Joshua
Raza, Sayyid
Baricevic-Jones, Ivona
Rengarajan, Sharmilee
Chinnadurai, Rajkumar
Kalra, Philip A.
Sinha, Smeeta
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 19 May 2025
Accepted: 3 September 2025
First Online: 24 October 2025
Declarations
:
: The Salford Kidney Study has been granted approval from the North West Greater Manchester South Research Ethics Committee (REC15/NW/0818). Informed consent to participate in research studies was obtained from all participants enrolled into the SKS. This study was conducted in accordance with the declaration of Helsinki.
: JS, SRa, IBJ, SRe and RC have no competing interests to report.PAK has the following competing interests: grant funding from Vifor and Astellas, consulting fees from Astra Zeneca, Vifor, Unicyte and UCB, honoraria from Vifor, Astra Zeneca and Pfizer, support for attending meetings from Pharmacosmos and Vifor.SS has the following competing interests: speaker/lecture fees from AstraZeneca, Bayer, Sanofi-Genzyme, Novartis, CSL Vifor Pharma, GSK, Menarini, Medscape; Advisory boards: Novartis, Bayer, Sanofi-Genzyme, Vifor Pharma, Boehringer Ingelheim, AstraZeneca and GSK; Clinical consultancy: Sanifit, Inozyme Pharma inc; Grants from Amgen, JnJ, AstraZeneca, CSL Vifor, Sanofi Genzyme.
